INmune Bio, Inc. (INMB) 追踪市盈率为负值 -0.7, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 1.3 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -137.67%, 前瞻盈利收益率 76.34%. PEG 0.01 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 55/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -147.4 | -0.33 | -273.56 | 0.00 | - |
| 2017 | -107.9 | -2.94 | 4.95 | 0.00 | - |
| 2018 | -7.2 | -0.01 | 5.42 | 0.00 | - |
| 2019 | -7.8 | 0.39 | 2.52 | 0.00 | - |
| 2020 | -17.1 | -1.27 | 5.33 | 18,766.67 | - |
| 2021 | -5.4 | -0.06 | 2.05 | 909.04 | - |
| 2022 | -4.2 | 0.22 | 1.89 | 303.90 | - |
| 2023 | -6.7 | -0.68 | 5.31 | 1,306.23 | - |
| 2024 | -2.2 | -0.08 | 2.90 | 6,652.75 | - |
| 2025 | -0.9 | 0.08 | 1.76 | 829.46 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-0.02 | $0.00 | $-277K | - |
| 2017 | $-0.07 | $0.00 | $-831K | - |
| 2018 | $-1.11 | $0.00 | $-12.44M | - |
| 2019 | $-0.89 | $0.00 | $-7.68M | - |
| 2020 | $-1.01 | $10.92K | $-12.1M | -110837.3% |
| 2021 | $-1.88 | $181K | $-30.34M | -16762.4% |
| 2022 | $-1.52 | $374K | $-27.3M | -7299.2% |
| 2023 | $-1.67 | $155K | $-30.01M | -19360% |
| 2024 | $-2.08 | $14K | $-42.08M | -300585.7% |
| 2025 | $0.00 | $50K | $-45.93M | -91866% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.94 | $-0.94 – $-0.94 | $133.33K | $133.33K – $133.33K | 2 |
| 2027 | $-0.97 | $-1.31 – $-0.64 | $6.69M | $6.53M – $6.86M | 2 |
| 2028 | $-0.31 | $-0.41 – $-0.21 | $31.92M | $31.92M – $31.92M | 2 |
| 2029 | $1.01 | $1.01 – $1.01 | $96.56M | $96.56M – $96.56M | 1 |
| 2030 | $2.49 | $2.49 – $2.49 | $168.59M | $168.59M – $168.59M | 1 |
